FDA has approved that a rapid blood test combining measurements of both GFAP and ubiquitin carboxyl-terminal hydrolase L1 (GFAP/ UCH-L1) to aid the diagnosis of acute traumatic intracranial injury (TII) after mTBI patients in April, 2018 [37]. This evidence concerns the gene GFAP and concussion.